Inactive Instrument

NOVARTIS Stock London S.E.

Equities

0HKE

CH0012005267

Pharmaceuticals

End-of-day quote London S.E.
- GBX - Intraday chart for NOVARTIS
Sales 2024 * 48.65B Sales 2025 * 49.87B Capitalization 210B
Net income 2024 * 9.52B Net income 2025 * 11.58B EV / Sales 2024 * 4.54 x
Net Debt 2024 * 10.94B Net Debt 2025 * 10.14B EV / Sales 2025 * 4.41 x
P/E ratio 2024 *
19.4 x
P/E ratio 2025 *
16.7 x
Employees -
Yield 2024 *
3.79%
Yield 2025 *
3.91%
Free-Float 81.95%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company